SEC Filing Summary: BioZone Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioZone Pharmaceuticals, Inc. on August 8, 2012. The filing addresses a material error discovered during a review of interim financial statements for the three and six months ended June 30, 2012. The error necessitates a restatement of the previously issued Quarterly Report on Form 10-Q for the period ended March 31, 2012.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the identification of accounting errors rather than the disclosure of current financial performance metrics.
Material Changes and Accounting Errors
The Company identified two specific misstatements in the financial statements for the period ended March 31, 2012:
- Expense Recharacterization: Certain expenses were incorrectly classified and must be recharacterized into a new line item for selling expenses.
- Convertible Promissory Notes: There was a misstatement regarding the accounting treatment for issuances of certain convertible promissory notes.
Consequently, the Chief Financial Officer concluded that the previously issued financial statements should no longer be relied upon.
Management Commentary and Outlook
Management, including the Chief Financial Officer and Controller, has discussed these matters with Paritz and Company, P.A., the Company's independent registered public accounting firm. The Company intends to restate the financial statements to correct these errors and will file an amendment to the Quarterly Report with the Securities and Exchange Commission. No forward-looking guidance or risk factors beyond the restatement were disclosed in this filing.
Investor Verification Checklist
- Verify the upcoming amended Form 10-Q for the period ended March 31, 2012, to review the restated financial figures.
- Confirm the specific dollar amounts associated with the recharacterized selling expenses and the convertible promissory note adjustments once the amendment is filed.
- Monitor for any additional disclosures regarding the impact of these errors on the Company's liquidity or debt covenants.